A detailed history of China Universal Asset Management Co., Ltd. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 16,071 shares of VERV stock, worth $84,372. This represents 0.03% of its overall portfolio holdings.

Number of Shares
16,071
Previous 16,071 -0.0%
Holding current value
$84,372
Previous $213,000 -0.0%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$10.81 - $17.96 $78,437 - $130,317
7,256 Added 82.31%
16,071 $213,000
Q4 2023

May 21, 2024

SELL
$8.84 - $18.7 $64,143 - $135,687
-7,256 Reduced 45.15%
8,815 $122,000
Q4 2023

Jan 23, 2024

BUY
$8.84 - $18.7 $63,418 - $134,153
7,174 Added 437.17%
8,815 $123,000
Q3 2023

May 21, 2024

BUY
$11.42 - $20.82 $9,467 - $17,259
829 Added 102.09%
1,641 $21,000
Q3 2023

Oct 30, 2023

BUY
$11.42 - $20.82 $9,467 - $17,259
829 Added 102.09%
1,641 $22,000
Q2 2023

May 21, 2024

SELL
$13.34 - $19.9 $306 - $457
-23 Reduced 2.75%
812 $15,000
Q2 2023

Jul 27, 2023

SELL
$13.34 - $19.9 $306 - $457
-23 Reduced 2.75%
812 $15,000
Q1 2023

May 21, 2024

BUY
$14.3 - $24.01 $2,988 - $5,018
209 Added 33.39%
835 $12,000
Q1 2023

Apr 27, 2023

BUY
$14.3 - $24.01 $2,988 - $5,018
209 Added 33.39%
835 $12,000
Q4 2022

May 21, 2024

SELL
$17.85 - $40.7 $275,693 - $628,611
-15,445 Reduced 96.1%
626 $12,000
Q4 2022

Jan 31, 2023

BUY
$17.85 - $40.7 $1,160 - $2,645
65 Added 11.59%
626 $12,000
Q3 2022

Oct 21, 2022

BUY
$15.63 - $41.49 $8,768 - $23,275
561 New
561 $19,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $315M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.